Advanced

Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

Kanerva, Anna; Koski, Anniina; Liikanen, Ilkka; Oksanen, Minna; Joensuu, Timo; Hemminki, Otto; Palmgren, Juni; Hemminki, Kari LU and Hemminki, Akseli (2015) In Molecular Therapy 23(2). p.321-329
Abstract
Oncolytic immunotherapy with cytokine armed replication competent viruses is an emerging approach in cancer treatment. In a recent randomized trial an increase in response rate was seen but the effect on overall survival is not known with any virus. To facilitate randomized trials, we performed a case-control study assessing the survival of 270 patients treated in an Advanced Therapy Access Program (ATAP), in comparison to matched concurrent controls from the same hospital. The overall survival of all virus treated patients was not increased over controls. However, when analysis was restricted to GMCSF-sensitive tumor types treated with GMSCF-coding viruses, a significant improvement in median survival was present (From 170 to 208 days, P... (More)
Oncolytic immunotherapy with cytokine armed replication competent viruses is an emerging approach in cancer treatment. In a recent randomized trial an increase in response rate was seen but the effect on overall survival is not known with any virus. To facilitate randomized trials, we performed a case-control study assessing the survival of 270 patients treated in an Advanced Therapy Access Program (ATAP), in comparison to matched concurrent controls from the same hospital. The overall survival of all virus treated patients was not increased over controls. However, when analysis was restricted to GMCSF-sensitive tumor types treated with GMSCF-coding viruses, a significant improvement in median survival was present (From 170 to 208 days, P = 0.0012, N=148). An even larger difference was seen when analysis was restricted to good performance score patients (193 versus 292 days, P = 0.034, N=90). The survival of ovarian cancer patients was especially promising as median survival nearly quadrupled (P = 0.0003, N=37). These preliminary data lend support to initiation of randomized clinical trials with GMCSF-coding oncolytic adenoviruses.Molecular Therapy (2014); doi:10.1038/mt.2014.218. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Molecular Therapy
volume
23
issue
2
pages
321 - 329
publisher
Nature Publishing Group
external identifiers
  • pmid:25381801
  • wos:000348750700013
  • scopus:84922262706
ISSN
1525-0024
DOI
10.1038/mt.2014.218
language
English
LU publication?
yes
id
dae7a98f-14c7-4f9e-b647-c77f723fe40c (old id 4817098)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25381801?dopt=Abstract
date added to LUP
2014-12-01 20:24:19
date last changed
2017-01-01 03:08:08
@article{dae7a98f-14c7-4f9e-b647-c77f723fe40c,
  abstract     = {Oncolytic immunotherapy with cytokine armed replication competent viruses is an emerging approach in cancer treatment. In a recent randomized trial an increase in response rate was seen but the effect on overall survival is not known with any virus. To facilitate randomized trials, we performed a case-control study assessing the survival of 270 patients treated in an Advanced Therapy Access Program (ATAP), in comparison to matched concurrent controls from the same hospital. The overall survival of all virus treated patients was not increased over controls. However, when analysis was restricted to GMCSF-sensitive tumor types treated with GMSCF-coding viruses, a significant improvement in median survival was present (From 170 to 208 days, P = 0.0012, N=148). An even larger difference was seen when analysis was restricted to good performance score patients (193 versus 292 days, P = 0.034, N=90). The survival of ovarian cancer patients was especially promising as median survival nearly quadrupled (P = 0.0003, N=37). These preliminary data lend support to initiation of randomized clinical trials with GMCSF-coding oncolytic adenoviruses.Molecular Therapy (2014); doi:10.1038/mt.2014.218.},
  author       = {Kanerva, Anna and Koski, Anniina and Liikanen, Ilkka and Oksanen, Minna and Joensuu, Timo and Hemminki, Otto and Palmgren, Juni and Hemminki, Kari and Hemminki, Akseli},
  issn         = {1525-0024},
  language     = {eng},
  number       = {2},
  pages        = {321--329},
  publisher    = {Nature Publishing Group},
  series       = {Molecular Therapy},
  title        = {Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.},
  url          = {http://dx.doi.org/10.1038/mt.2014.218},
  volume       = {23},
  year         = {2015},
}